$1.6 B

BOLD Mkt cap, 10-Jun-2019
Audentes Therapeutics Net income (Q1, 2019)-49.4 M
Audentes Therapeutics EBIT (Q1, 2019)-51.8 M
Audentes Therapeutics Cash, 31-Mar-2019133.2 M

Audentes Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

R&D expense

48.8m75.9m104.4m

General and administrative expense

11.3m17.3m30.0m

Operating expense total

60.0m93.2m134.4m

EBIT

(60.0m)(93.2m)(134.4m)

Interest income

472.0k767.0k6.0m

Pre tax profit

(92.5m)(128.8m)

Income tax expense

2.2m

Net Income

(59.7m)(90.2m)(128.8m)

Audentes Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(59.7m)(90.2m)(128.8m)

Depreciation and Amortization

1.6m3.4m5.6m

Accounts Payable

(671.0k)686.0k4.1m

Cash From Operating Activities

(49.0m)(84.5m)(108.0m)

Purchases of PP&E

(16.7m)(7.6m)(11.6m)

Cash From Investing Activities

(62.0m)(33.4m)(185.0m)

Cash From Financing Activities

75.4m120.6m398.5m

Audentes Therapeutics Ratios

USDY, 2019

Financial Leverage

1.1 x

Audentes Therapeutics Employee Rating

3.215 votes
Culture & Values
3.4
Work/Life Balance
3.2
Senior Management
3.2
Salary & Benefits
4.6
Career Opportunities
3.9
Source